查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1836846

胚胎胚胎著床前基因檢測市場（按檢測類型、檢測技術類型、提供的服務和最終用戶分類）—2025-2032 年全球預測

Preimplantation Genetic Testing Market by Testing Type, Test Type, Technology Type, Offering, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，胚胎著床前基因檢測市場規模將成長至 20.092 億美元，複合年成長率為 12.55%。

主要市場統計數據
基準年2024年 7.8019億美元
預計2025年 8.7374億美元
預測年份：2032年 20.92億美元
複合年成長率（%） 12.55%

胚胎著床前基因檢測的引人注目的方向構成了臨床整合、技術成熟和不斷變化的相關人員的期望

胚胎著床前基因檢測已從輔助生殖的專業輔助手段轉變為生殖遺傳學和個人化生殖醫學的核心組成部分。如今，臨床醫生、實驗室主任和機構領導都重視基因檢測，將其視為胚胎選擇、降低單基因疾病風險以及最佳化臨床結果的重要組成部分。在監管預期不斷變化和支付方態度轉變的背景下，實驗室和診所面臨越來越大的壓力，需要確保診斷準確性、簡化工作流程，並向患者和轉診網路證明其臨床效用。

技術進步正在縮短週轉時間，提高解析度，並使臨床決策更加清晰，同時也為與生物資訊學和電子健康記錄的整合開闢了新的途徑。同時，患者對透明度、諮詢和可近性的期望正在重塑服務提供模式。患者越來越要求清晰地解釋檢測的範圍、局限性以及對生育選擇的後續影響。因此，胚胎學家、遺傳諮詢師、實驗室科學家和資訊學專業人員之間的跨職能合作對於提供臨床上可靠且符合倫理的檢測項目至關重要。

展望未來，相關人員必須專注於將臨床證據與營運可擴展性結合。實驗室和生殖服務提供者必須協調高通量、可重複檢測的需求與個人化患者照護。同時，研究機構和診斷合作夥伴正在擴大其轉化研究，以改善變異解讀、檢驗新型檢測方法並擴展檢測適應症。本介紹為深入評估影響胚胎胚胎著床前基因檢測格局的變革性變化奠定了基礎。

融合的技術創新、不斷發展的臨床工作流程和監管改進如何重塑生殖遺傳學的檢測實踐和患者路徑

在臨床、技術和監管力量融合的推動下，胚胎胚胎著床前基因檢測領域正在經歷變革性變革。定序準確性和生物資訊學演算法的進步提高了胚胎遺傳評估的解析度，使得對非整倍體、結構重排和單基因變異的檢測更加精準。因此，實驗室正在從單一方法模式轉向將高通量定序與標靶確認檢測相結合的混合工作流程，從而在兼顧成本和通量的同時提高診斷可信度。

同時，臨床生態系統正在適應患者日益成長的需求，即對全面遺傳學洞察和清晰的諮詢框架的需求。遺傳諮詢已成為病人歷程就診體驗的核心，有助於做出明智的決策並進行風險溝通。同時，支付方和醫療系統開始更嚴格地審查臨床價值提案，鼓勵醫療服務提供者收集結果數據並展示其檢測策略的實際效用。監管機構也在加強審查力度，提高對分析和臨床驗證、實驗室認證以及診斷檢測上市後監管的期望。

在營運方面，供應鏈彈性和試劑標準化已成為實驗室規劃的重中之重，推動了庫存管理和多元化採購的投資。在更高層面，生育診所、診斷實驗室和專業軟體提供者之間的策略聯盟正在加速發展，以創造出將實驗室服務與分析、報告和病人參與結合的垂直整合解決方案。這些轉型正在全面重塑檢測的交付方式、報銷方式以及患者和臨床醫生的認知。

評估 2025 年關稅上調對診斷和生育服務提供者的供應鏈、籌資策略和營運彈性的系統性影響

2025年推出的高關稅措施和貿易限制措施，增加了對支撐基因檢測工作流程的跨國供應鏈的審查。進口附加稅和累積關稅調整增加了專用設備、試劑和耗材的到岸成本，給依賴國際供應商的診斷實驗室和生育中心帶來了直接的財務壓力。因此，許多機構正在重新審視籌資策略，優先選擇擁有強大本地分銷網路和替代採購管道的供應商，以減輕關稅波動的影響。

這些貿易動態對資本投資和服務交付產生了連鎖影響。考慮購買新設備的醫療保健機構不僅考慮購買價格，還考慮長期維護、備件供應和試劑採購風險。因此，採購週期不斷延長，資本配置決策也優先考慮總擁有成本透明且物流彈性強的供應商。一些機構也正在加速整合區域網路採購，並簽訂長期供應協議，以穩定價格和供應。

除了採購之外，關稅也重新激發了人們對近岸外包和區域製造夥伴關係的興趣。相關人員正在評估本地化組件組裝和試劑生產的機會，以減少進口關稅的影響並縮短補貨交付前置作業時間。同時，實驗室正在投資於流程最佳化和檢測穩健性，以減少對單一來源試劑的依賴。簡言之，2025年關稅變動的累積影響更重視供應鏈敏捷性、本地夥伴關係發展與採購管治，並將其視為營運韌性的基本要素。

將測試類別、調查方法平台、行銷產品和最終用戶採用模式與策略重點連結起來的詳細細分洞察

細分分析揭示了檢測類型、檢測格式、技術、產品和最終用戶之間不同的臨床和商業性動態。根據檢測類型，用於非整倍體檢測的 PGT-A、用於單基因疾病的 PGT-M 和用於結構重排的 PGT-SR 之間的差異凸顯了不同的實驗室工作流程、諮詢需求和證據標準。例如，PGT-M 計畫通常需要密集的家族特異性檢測開發和深度的臨床基因整合，而 PGT-A 工作流程則優先考慮高通量非整倍體篩檢和簡化的報告流程。根據檢測類型胚胎著床前遺傳學診斷與胚胎著床前遺傳學篩檢分開來，凸顯了臨床意圖和患者諮詢的差異。診斷通常側重於已知的遺傳性突變並提供有針對性的解讀，而篩檢強調更廣泛的染色體評估和人群層面的風險分層。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 採用非侵入性胚胎檢測技術，透過廢培養基分析來改善基因篩檢結果
  • 整合人工智慧和機器學習演算法，實現胚胎著床前測試中的自動化胚胎評估
  • 擴大單基因和多基因疾病的胚胎著床前基因檢測，以支持個人化生殖計劃
  • 可攜式次世代定序平台的出現，使得快速且經濟高效的胚胎著床前遺傳分析成為可能
  • 不斷發展的倫理準則和法律規範正在塑造胚胎著床前基因檢測實踐的全球標準
  • 遠端醫療遺傳諮詢的需求正在增加，以改善偏遠地區獲得胚胎著床前檢測服務的機會
  • 生育診所與生技公司建立策略夥伴關係，加速胚胎胚胎著床前基因檢測創新
  • 全基因組定序成本的降低將增加綜合胚胎著床前篩檢解決方案的採用
  • 人們對透過數位生育平台直接面對消費者的胚胎著床前基因篩檢服務的興趣日益濃厚
  • 關注健康公平舉措，擴大醫療服務涵蓋缺醫少藥族群

第6章：2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

第8章胚胎著床前基因檢測市場（依檢測類型）

  • PGT-A（非整倍體）
  • PGT-M（單基因疾病）
  • PGT-SR（結構重建）

第9章：胚胎胚胎著床前基因檢測市場（依檢測類型）

  • 胚胎著床前基因診斷
  • 胚胎胚胎著床前基因篩檢

第 10 章 胚胎胚胎著床前基因檢測市場（依技術類型）

  • 比較基因組雜合反應
  • 螢光原位雜合技術
  • 次世代定序
  • PCR檢測
  • 單核苷酸多態性

第 11 章 胚胎胚胎著床前基因檢測市場（依產品提供）

  • 裝置
  • 試劑和耗材
  • 軟體

第12章 胚胎胚胎著床前基因檢測市場（依最終用戶分類）

  • 診斷實驗室
  • 不孕不育診所
  • 醫院
  • 研究機構

第13章 胚胎胚胎著床前基因檢測市場（按地區）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章胚胎著床前基因檢測市場（依類別）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國胚胎胚胎著床前基因檢測市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Abbott Laboratories
    • Agilent Technologies, Inc.
    • Bio-Techne Corporation
    • Bioarray SL
    • EUROPE IVF International sro
    • F. Hoffmann-La Roche AG
    • Genea Limited
    • GENETiKS
    • Illumina, Inc.
    • Invicta Genetics
    • Invitae Corporation
    • Juno Genetics, US Inc.
    • Laboratory Corporation of America Holdings
    • MedGenome Labs Ltd.
    • Merck KGaA
    • Natera, Inc.
    • NextGen Genetics Holdings, LLC
    • Ovation Fertility
    • PacGenomics
    • PerkinElmer, Inc.
    • Progyny, Inc.
    • Qiagen NV
    • Quest Diagnostics Incorporated
    • Reproductive Genetic Innovations, LLC
    • SEQUENCE46, LLC
    • Sysmex Corporation
    • Takara Bio Inc.
    • The Cooper Companies Inc.
    • Thermo Fisher Scientific Inc.
    • Vitrolife Sweden AB
    • Yikon Genomics（Shanghai）Co., Ltd.
Product Code: MRR-030EE48515DA

The Preimplantation Genetic Testing Market is projected to grow by USD 2,009.20 million at a CAGR of 12.55% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 780.19 million
Estimated Year [2025] USD 873.74 million
Forecast Year [2032] USD 2,009.20 million
CAGR (%) 12.55%

A compelling orientation to preimplantation genetic testing that frames clinical integration, technological maturation, and evolving stakeholder expectations

Preimplantation genetic testing has moved from a specialized adjunct to assisted reproduction into a core element of reproductive genetics and personalized reproductive care. Clinicians, laboratory directors, and institutional leaders now evaluate genetic testing as an integral part of embryo selection, risk mitigation for monogenic disorders, and optimizing clinical outcomes. Against a backdrop of evolving regulatory expectations and shifting payer attitudes, laboratories and clinics face heightened pressure to ensure diagnostic accuracy, streamline workflows, and demonstrate clinical utility to both patients and referral networks.

Technological progress has compressed turnaround times and improved resolution, enabling more definitive clinical decision-making while opening new pathways for integration with bioinformatics and electronic health records. Concurrently, patient expectations around transparency, counseling, and access are reshaping service delivery models; patients increasingly demand clear explanations of test scope, limitations, and the downstream implications for reproductive choices. As a result, cross-functional collaboration among embryologists, genetic counselors, laboratory scientists, and informatics specialists has become essential for delivering clinically robust and ethically sound testing programs.

Looking ahead, stakeholder imperatives center on harmonizing clinical evidence with operational scalability. Laboratories and fertility providers must reconcile the need for high-throughput, reproducible assays with individualized patient care. At the same time, research institutions and diagnostic partners are expanding translational efforts to refine variant interpretation, validate novel assays, and expand testing indications. This introduction sets the stage for a deeper appraisal of the transformative shifts reshaping the preimplantation genetic testing landscape.

How converging technological innovations, evolving clinical workflows, and regulatory refinements are reshaping testing operations and patient pathways in reproductive genetics

The preimplantation genetic testing environment is undergoing transformative shifts driven by converging clinical, technological, and regulatory forces. Advances in sequencing accuracy and bioinformatic algorithms have increased the resolution of embryo genetic assessment, enabling more nuanced detection of aneuploidy, structural rearrangements, and single-gene variants. Consequently, laboratories are transitioning from single-method paradigms to hybrid workflows that combine high-throughput sequencing with targeted confirmatory assays, thereby improving diagnostic confidence while managing cost and throughput considerations.

Simultaneously, the clinical ecosystem is adapting to greater patient demand for comprehensive genetic insight coupled with clear counseling frameworks. Genetic counseling has become more central to the patient journey, facilitating informed decision-making and risk communication. In parallel, payers and health systems are beginning to scrutinize clinical value propositions more closely, which is prompting providers to collect outcomes data and demonstrate the real-world utility of testing strategies. Regulatory authorities are also refining oversight, with increased expectations for analytical and clinical validation, laboratory accreditation, and post-market surveillance of diagnostic assays.

Operationally, supply chain resilience and reagent standardization have moved to the forefront of laboratory planning, prompting investments in inventory management and diversified sourcing. At a higher level, strategic alliances between fertility clinics, diagnostic laboratories, and specialist software providers are accelerating to create vertically integrated solutions that combine laboratory services with analytics, reporting, and patient engagement. These transformative shifts are collectively reshaping how testing is delivered, reimbursed, and perceived by patients and clinicians alike.

Assessing the systemic consequences of 2025 tariff changes on supply chains, procurement strategies, and operational resilience across diagnostic and fertility providers

The introduction of elevated tariff measures and trade restrictions in 2025 has intensified scrutiny of cross-border supply chains that support genetic testing workflows. Import levies and cumulative tariff adjustments have increased landed costs for specialized instruments, reagents, and consumables, creating immediate operational pressure for diagnostic laboratories and fertility centers that depend on international suppliers. In response, many organizations have re-evaluated procurement strategies to prioritize suppliers with robust local distribution networks or alternative sourcing channels that mitigate exposure to tariff volatility.

These trade dynamics have cascading implications for capital investment and service delivery. Institutions contemplating new instrument acquisitions are weighing not only acquisition price but also long-term maintenance, spare parts availability, and reagent procurement risk. As a result, procurement cycles have elongated and capital allocation decisions have been re-prioritized to favor suppliers with transparent total cost of ownership and resilient logistics. Some providers have also accelerated efforts to aggregate purchasing across regional networks or enter into long-term supply agreements to stabilize pricing and availability.

Beyond procurement, tariffs have spurred renewed interest in nearshoring and regional manufacturing partnerships. Stakeholders are evaluating opportunities to localize component assembly or reagent production to reduce exposure to import duties and expedite replenishment lead times. At the same time, laboratories are investing in process optimization and assay robustness to reduce dependency on single-source reagents. In short, the cumulative impact of tariff changes in 2025 has heightened emphasis on supply chain agility, local partnership development, and procurement governance as fundamental elements of operational resilience.

In-depth segmentation insights that connect testing categories, methodological platforms, commercial offerings, and end-user adoption patterns to strategic priorities

Segmentation analysis reveals differentiated clinical and commercial dynamics across testing types, test formats, technologies, offerings, and end users. Based on testing type, distinctions among PGT-A for aneuploidy detection, PGT-M for monogenic disorders, and PGT-SR for structural rearrangements highlight divergent laboratory workflows, counseling needs, and evidentiary standards; for example, PGT-M programs often require intensive family-specific assay development and deep clinical-genetic integration, whereas PGT-A workflows prioritize high-throughput aneuploidy screening and streamlined reporting. Based on test type, the separation between preimplantation genetic diagnosis and preimplantation genetic screening underscores differences in clinical intent and patient counseling; diagnosis is typically focused on known familial variants and targeted interpretation, while screening emphasizes broader chromosomal assessment and population-level risk stratification.

Based on technology type, the competitive dynamics hinge on methodological trade-offs among comparative genomic hybridization, fluorescent in-situ hybridization, next-generation sequencing, PCR-based testing, and single-nucleotide polymorphism arrays. Next-generation sequencing is increasingly favored for its scalability and resolution, yet PCR-based and SNP approaches retain roles in confirmatory testing and specific assay designs. Comparative genomic hybridization and FISH continue to be relevant for certain structural assessments and regulatory-validated workflows, especially where orthogonal confirmation is required. Based on offering, the ecosystem separates into instruments, reagents and consumables, and software; instruments drive capital expenditure and laboratory footprint decisions, reagents and consumables determine recurring operating costs and supply chain exposure, and software governs data interpretation, reporting, and integration with clinical systems. Based on end user, diagnostic laboratories, fertility clinics, hospitals, and research institutes exhibit variable adoption patterns; diagnostic laboratories prioritize standardized, high-throughput workflows and accreditation, fertility clinics focus on turnaround time and counseling integration, hospitals emphasize interdisciplinary coordination and inpatient pathways, and research institutes prioritize methodological innovation and validation pathways. Together, these segmentation lenses illuminate where clinical needs, operational constraints, and commercial opportunities intersect, enabling stakeholders to prioritize investments and partnerships aligned with their strategic capabilities.

How regional regulatory frameworks, payer environments, and clinical adoption patterns are shaping differentiated strategies in the Americas, Europe, Middle East & Africa, and Asia-Pacific

Regional dynamics shape both service delivery models and strategic partnerships across the preimplantation genetic testing landscape. Americas maintain a combination of advanced clinical adoption in major urban centers and rapid innovation diffusion through private fertility networks, which has led to a dense ecosystem of specialized laboratories, referral clinics, and academic collaborators. In contrast, Europe, Middle East & Africa presents a mosaic of regulatory frameworks and payer models; pockets of highly advanced public and private centers coexist with regions where access is constrained, driving cross-border patient mobility and centralized laboratory services. This regional heterogeneity encourages pan-regional laboratory networks and standardized reporting approaches to address cross-jurisdictional clinical needs.

Asia-Pacific exhibits heterogenous trajectories as well, with select markets demonstrating rapid scale-up of assisted reproductive services, strong private-sector investment, and increased local capability in genomics. At the same time, several markets in the region are investing in capacity-building and regulatory frameworks to support clinical validation and ethical oversight. Across all regions, differences in reimbursement landscapes, regulatory expectations, and cultural perspectives on reproductive genetics influence service models, patient counseling practices, and commercialization strategies. As a result, successful regional approaches blend localized clinical pathways with global best practices in quality management and evidence generation, enabling providers to deliver consistent, ethically grounded, and operationally sustainable testing services.

Corporate strategies and partnership dynamics revealing how integration, specialization, and collaboration are redefining competitive advantage across diagnostics and service providers

Company-level dynamics in the preimplantation genetic testing space reflect a mix of vertical integration, strategic specialization, and collaborative ecosystems. Some organizations have concentrated on end-to-end solutions that combine instrumentation, reagents, and interpretive software to deliver turnkey offerings for fertility clinics and centralized laboratories. Other players have focused on niche strengths such as assay development for rare monogenic disorders, high-resolution structural variant detection, or cloud-native analytics for variant interpretation and reporting. In parallel, laboratory service providers have expanded clinical partnerships and referral networks to offer outsourced testing with standardized quality controls and consolidated reporting frameworks.

Partnerships and alliance formation have emerged as a primary vector for capability expansion. Commercial agreements between diagnostic laboratories and fertility networks, as well as collaborations with software vendors for integrated reporting, have enabled faster market entry and reduced the need for duplicative capital investment. In addition, strategic investments in regulatory compliance and accreditation have become competitive differentiators for laboratories seeking to serve international referral markets. Mergers and acquisitions continue to reconfigure the competitive terrain, especially where scale affords supply chain leverage, broader test menus, and enhanced data assets for variant curation. Collectively, these company insights underscore the importance of aligning technical capabilities with clear commercial pathways and compliance infrastructure to sustain growth and clinical credibility.

Practical, high-impact strategies that industry stakeholders can implement to enhance evidence generation, supply chain resilience, informatics integration, and patient-centered service delivery

Industry leaders can take decisive actions to strengthen clinical relevance, operational resilience, and commercial differentiation. First, prioritize investment in assay validation and clinical evidence that demonstrate real-world utility across diverse patient cohorts and clinical pathways; such evidence supports stronger clinician adoption and more effective communication of value to payers and institutional buyers. Second, cultivate resilient supply chains through multi-source procurement, regional distributor partnerships, and inventory strategies that mitigate exposure to tariff-driven or geopolitical disruptions. By emphasizing transparent total cost of ownership and predictable replenishment, organizations can reduce service interruptions and protect margins.

Third, accelerate integration of robust bioinformatics and interpretive software to standardize reporting, improve turnaround time, and enhance variant curation workflows. Interoperability with electronic health records and laboratory information systems will be a significant factor in clinician acceptance and cross-disciplinary coordination. Fourth, embed genetic counseling into the patient pathway to ensure informed consent, appropriate expectation-setting, and patient-centered communication about test scope and limitations. Finally, pursue strategic alliances and partnership models that combine clinical expertise, laboratory scale, and data analytics to unlock synergies while preserving regulatory compliance. These actions, when implemented in concert, create a defensible position that addresses both near-term operational risks and longer-term strategic growth.

Transparent and rigorous research methodology combining primary expert interviews, secondary evidence synthesis, and iterative validation to ensure robust and actionable insights

The research methodology underpinning this analysis blends primary expert engagement with structured secondary synthesis and iterative validation. Primary research included in-depth interviews with clinical laboratory leaders, embryologists, genetic counselors, procurement officers, and regulatory specialists to capture operational realities, clinical decision drivers, and procurement constraints. These qualitative insights were complemented by technical assessments of prevailing assay methodologies, analytical performance characteristics, and workflow integration challenges, drawing on peer-reviewed literature and technical white papers to ensure methodological rigor.

Secondary synthesis involved systematic review of clinical guidelines, professional society statements, and regulatory advisories to align the analysis with current standards of practice and compliance expectations. Data triangulation was used to reconcile divergent inputs and to surface consistent patterns across respondent groups and documented sources. Finally, findings underwent internal peer review and scenario stress-testing to evaluate sensitivity to supply chain disruptions, tariff variations, and technology adoption trajectories. The combined methodology ensures that conclusions are grounded in both frontline operational experience and documented best practices, providing a reliable basis for decision-making and strategic planning.

A definitive synthesis of the strategic imperatives, operational challenges, and clinical enablers that will determine sustainable adoption and long-term integration of genetic testing in reproductive care

In synthesis, preimplantation genetic testing stands at an inflection point where technological maturation, patient expectations, and operational realities converge to reshape service delivery. Laboratories and fertility providers must balance the need for high analytical performance with scalable workflows and resilient supply chains. The evolving regulatory environment and payer scrutiny will reward organizations that prioritize rigorous validation, clear clinical evidence, and demonstrable quality controls. At the same time, investments in bioinformatics, interpretive software, and integrated counseling pathways will be decisive in delivering patient-centered care and supporting clinician adoption.

Strategically, stakeholders that pursue collaborative models-combining laboratory excellence, clinical partnerships, and software-enabled reporting-are best positioned to translate technical capability into sustainable clinical services. Moreover, pragmatic procurement and regional partnership strategies will mitigate exposure to trade disruptions and tariff-related cost pressures. Looking forward, the sector's ability to standardize quality metrics, improve variant interpretation, and communicate clinical utility effectively will determine its broader acceptance and long-term integration into reproductive health practice. These conclusions underscore the imperative for coordinated action across clinical, operational, and commercial domains to realize the full potential of preimplantation genetic testing.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Adoption of noninvasive embryo testing techniques through spent culture media analysis for improved genetic screening outcomes
  • 5.2. Integration of artificial intelligence and machine learning algorithms for automated embryo evaluation in preimplantation testing
  • 5.3. Expansion of preimplantation genetic testing for monogenic and polygenic disorders to support personalized reproductive planning
  • 5.4. Emergence of portable next-generation sequencing platforms enabling rapid and cost-effective preimplantation genetic analysis
  • 5.5. Evolving ethical guidelines and regulatory frameworks shaping global standards for preimplantation genetic testing practice
  • 5.6. Growing demand for telehealth-enabled genetic consultations to enhance access to preimplantation testing services in remote regions
  • 5.7. Strategic partnerships between fertility clinics and biotechnology firms to accelerate innovation in preimplantation genetic testing
  • 5.8. Increasing affordability of whole genome sequencing driving broader adoption of comprehensive preimplantation screening solutions
  • 5.9. Rising interest in direct-to-consumer preimplantation genetic screening offerings through digital fertility platforms
  • 5.10. Focus on health equity initiatives to expand preimplantation genetic testing availability in underserved populations

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Preimplantation Genetic Testing Market, by Testing Type

  • 8.1. PGT-A (Aneuploidy)
  • 8.2. PGT-M (Monogenic Disorders)
  • 8.3. PGT-SR (Structural Rearrangements)

9. Preimplantation Genetic Testing Market, by Test Type

  • 9.1. Preimplantation Genetic Diagnosis
  • 9.2. Preimplantation Genetic Screening

10. Preimplantation Genetic Testing Market, by Technology Type

  • 10.1. Comparative Genomic Hybridization
  • 10.2. Fluorescent In-Situ Hybridization
  • 10.3. Next-Generation Sequencing
  • 10.4. PCR-Based Testing
  • 10.5. Single-Nucleotide Polymorphism

11. Preimplantation Genetic Testing Market, by Offering

  • 11.1. Instruments
  • 11.2. Reagents & Consumables
  • 11.3. Software

12. Preimplantation Genetic Testing Market, by End User

  • 12.1. Diagnostic Laboratories
  • 12.2. Fertility Clinics
  • 12.3. Hospitals
  • 12.4. Research Institutes

13. Preimplantation Genetic Testing Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Preimplantation Genetic Testing Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Preimplantation Genetic Testing Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Abbott Laboratories
    • 16.3.2. Agilent Technologies, Inc.
    • 16.3.3. Bio-Techne Corporation
    • 16.3.4. Bioarray S.L.
    • 16.3.5. EUROPE IVF International s.r.o.
    • 16.3.6. F. Hoffmann-La Roche AG
    • 16.3.7. Genea Limited
    • 16.3.8. GENETiKS
    • 16.3.9. Illumina, Inc.
    • 16.3.10. Invicta Genetics
    • 16.3.11. Invitae Corporation
    • 16.3.12. Juno Genetics, US Inc.
    • 16.3.13. Laboratory Corporation of America Holdings
    • 16.3.14. MedGenome Labs Ltd.
    • 16.3.15. Merck KGaA
    • 16.3.16. Natera, Inc.
    • 16.3.17. NextGen Genetics Holdings, LLC
    • 16.3.18. Ovation Fertility
    • 16.3.19. PacGenomics
    • 16.3.20. PerkinElmer, Inc.
    • 16.3.21. Progyny, Inc.
    • 16.3.22. Qiagen N.V.
    • 16.3.23. Quest Diagnostics Incorporated
    • 16.3.24. Reproductive Genetic Innovations, LLC
    • 16.3.25. SEQUENCE46, LLC
    • 16.3.26. Sysmex Corporation
    • 16.3.27. Takara Bio Inc.
    • 16.3.28. The Cooper Companies Inc.
    • 16.3.29. Thermo Fisher Scientific Inc.
    • 16.3.30. Vitrolife Sweden AB
    • 16.3.31. Yikon Genomics (Shanghai) Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. PREIMPLANTATION GENETIC TESTING MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. PREIMPLANTATION GENETIC TESTING MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. PREIMPLANTATION GENETIC TESTING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PGT-A (ANEUPLOIDY), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PGT-A (ANEUPLOIDY), BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PGT-A (ANEUPLOIDY), BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PGT-A (ANEUPLOIDY), BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PGT-A (ANEUPLOIDY), BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PGT-A (ANEUPLOIDY), BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PGT-M (MONOGENIC DISORDERS), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PGT-M (MONOGENIC DISORDERS), BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PGT-M (MONOGENIC DISORDERS), BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PGT-M (MONOGENIC DISORDERS), BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PGT-M (MONOGENIC DISORDERS), BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PGT-M (MONOGENIC DISORDERS), BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PGT-SR (STRUCTURAL REARRANGEMENTS), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PGT-SR (STRUCTURAL REARRANGEMENTS), BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PGT-SR (STRUCTURAL REARRANGEMENTS), BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PGT-SR (STRUCTURAL REARRANGEMENTS), BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PGT-SR (STRUCTURAL REARRANGEMENTS), BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PGT-SR (STRUCTURAL REARRANGEMENTS), BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PREIMPLANTATION GENETIC DIAGNOSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PREIMPLANTATION GENETIC DIAGNOSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PREIMPLANTATION GENETIC DIAGNOSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PREIMPLANTATION GENETIC DIAGNOSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PREIMPLANTATION GENETIC DIAGNOSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PREIMPLANTATION GENETIC DIAGNOSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PREIMPLANTATION GENETIC SCREENING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PREIMPLANTATION GENETIC SCREENING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PREIMPLANTATION GENETIC SCREENING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PREIMPLANTATION GENETIC SCREENING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PREIMPLANTATION GENETIC SCREENING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PREIMPLANTATION GENETIC SCREENING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COMPARATIVE GENOMIC HYBRIDIZATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COMPARATIVE GENOMIC HYBRIDIZATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COMPARATIVE GENOMIC HYBRIDIZATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COMPARATIVE GENOMIC HYBRIDIZATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COMPARATIVE GENOMIC HYBRIDIZATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COMPARATIVE GENOMIC HYBRIDIZATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY FLUORESCENT IN-SITU HYBRIDIZATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY FLUORESCENT IN-SITU HYBRIDIZATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY FLUORESCENT IN-SITU HYBRIDIZATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY FLUORESCENT IN-SITU HYBRIDIZATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY FLUORESCENT IN-SITU HYBRIDIZATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY FLUORESCENT IN-SITU HYBRIDIZATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PCR-BASED TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PCR-BASED TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PCR-BASED TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PCR-BASED TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PCR-BASED TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PCR-BASED TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY SINGLE-NUCLEOTIDE POLYMORPHISM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY SINGLE-NUCLEOTIDE POLYMORPHISM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY SINGLE-NUCLEOTIDE POLYMORPHISM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY SINGLE-NUCLEOTIDE POLYMORPHISM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY SINGLE-NUCLEOTIDE POLYMORPHISM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY SINGLE-NUCLEOTIDE POLYMORPHISM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY SOFTWARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY SOFTWARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY SOFTWARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY SOFTWARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY SOFTWARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY FERTILITY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY FERTILITY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY FERTILITY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY FERTILITY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY FERTILITY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY FERTILITY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. AMERICAS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 120. AMERICAS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 121. AMERICAS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2024 (USD MILLION)
  • TABLE 122. AMERICAS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2025-2032 (USD MILLION)
  • TABLE 123. AMERICAS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 124. AMERICAS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 125. AMERICAS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2024 (USD MILLION)
  • TABLE 126. AMERICAS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2025-2032 (USD MILLION)
  • TABLE 127. AMERICAS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 128. AMERICAS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2025-2032 (USD MILLION)
  • TABLE 129. AMERICAS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 130. AMERICAS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 131. NORTH AMERICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. NORTH AMERICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2024 (USD MILLION)
  • TABLE 134. NORTH AMERICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2025-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 136. NORTH AMERICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 137. NORTH AMERICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2024 (USD MILLION)
  • TABLE 138. NORTH AMERICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2025-2032 (USD MILLION)
  • TABLE 139. NORTH AMERICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 140. NORTH AMERICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2025-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 142. NORTH AMERICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 143. LATIN AMERICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. LATIN AMERICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. LATIN AMERICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2024 (USD MILLION)
  • TABLE 146. LATIN AMERICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2025-2032 (USD MILLION)
  • TABLE 147. LATIN AMERICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 148. LATIN AMERICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2024 (USD MILLION)
  • TABLE 150. LATIN AMERICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2025-2032 (USD MILLION)
  • TABLE 151. LATIN AMERICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 152. LATIN AMERICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2025-2032 (USD MILLION)
  • TABLE 153. LATIN AMERICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 154. LATIN AMERICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2024 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2025-2032 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 161. EUROPE, MIDDLE EAST & AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2024 (USD MILLION)
  • TABLE 162. EUROPE, MIDDLE EAST & AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2025-2032 (USD MILLION)
  • TABLE 163. EUROPE, MIDDLE EAST & AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 164. EUROPE, MIDDLE EAST & AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2025-2032 (USD MILLION)
  • TABLE 165. EUROPE, MIDDLE EAST & AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 166. EUROPE, MIDDLE EAST & AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 167. EUROPE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. EUROPE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. EUROPE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2024 (USD MILLION)
  • TABLE 170. EUROPE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2025-2032 (USD MILLION)
  • TABLE 171. EUROPE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 172. EUROPE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 173. EUROPE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2024 (USD MILLION)
  • TABLE 174. EUROPE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2025-2032 (USD MILLION)
  • TABLE 175. EUROPE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 176. EUROPE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2025-2032 (USD MILLION)
  • TABLE 177. EUROPE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 178. EUROPE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 179. MIDDLE EAST PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. MIDDLE EAST PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. MIDDLE EAST PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2024 (USD MILLION)
  • TABLE 182. MIDDLE EAST PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2025-2032 (USD MILLION)
  • TABLE 183. MIDDLE EAST PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 184. MIDDLE EAST PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 185. MIDDLE EAST PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2024 (USD MILLION)
  • TABLE 186. MIDDLE EAST PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2025-2032 (USD MILLION)
  • TABLE 187. MIDDLE EAST PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 188. MIDDLE EAST PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2025-2032 (USD MILLION)
  • TABLE 189. MIDDLE EAST PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 190. MIDDLE EAST PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 191. AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2024 (USD MILLION)
  • TABLE 194. AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2025-2032 (USD MILLION)
  • TABLE 195. AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 196. AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 197. AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2024 (USD MILLION)
  • TABLE 198. AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2025-2032 (USD MILLION)
  • TABLE 199. AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 200. AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2025-2032 (USD MILLION)
  • TABLE 201. AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 202. AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 203. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2024 (USD MILLION)
  • TABLE 206. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2025-2032 (USD MILLION)
  • TABLE 207. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 208. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 209. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2024 (USD MILLION)
  • TABLE 210. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2025-2032 (USD MILLION)
  • TABLE 211. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 212. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2025-2032 (USD MILLION)
  • TABLE 213. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 214. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 217. ASEAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. ASEAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. ASEAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2024 (USD MILLION)
  • TABLE 220. ASEAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2025-2032 (USD MILLION)
  • TABLE 221. ASEAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 222. ASEAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 223. ASEAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2024 (USD MILLION)
  • TABLE 224. ASEAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2025-2032 (USD MILLION)
  • TABLE 225. ASEAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 226. ASEAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2025-2032 (USD MILLION)
  • TABLE 227. ASEAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 228. ASEAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 229. GCC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 230. GCC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 231. GCC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2024 (USD MILLION)
  • TABLE 232. GCC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2025-2032 (USD MILLION)
  • TABLE 233. GCC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 234. GCC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 235. GCC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2024 (USD MILLION)
  • TABLE 236. GCC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2025-2032 (USD MILLION)
  • TABLE 237. GCC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 238. GCC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2025-2032 (USD MILLION)
  • TABLE 239. GCC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 240. GCC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 241. EUROPEAN UNION PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 242. EUROPEAN UNION PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 243. EUROPEAN UNION PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2024 (USD MILLION)
  • TABLE 244. EUROPEAN UNION PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2025-2032 (USD MILLION)
  • TABLE 245. EUROPEAN UNION PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 246. EUROPEAN UNION PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 247. EUROPEAN UNION PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2024 (USD MILLION)
  • TABLE 248. EUROPEAN UNION PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2025-2032 (USD MILLION)
  • TABLE 249. EUROPEAN UNION PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 250. EUROPEAN UNION PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2025-2032 (USD MILLION)
  • TABLE 251. EUROPEAN UNION PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 252. EUROPEAN UNION PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 253. BRICS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 254. BRICS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 255. BRICS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2024 (USD MILLION)
  • TABLE 256. BRICS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2025-2032 (USD MILLION)
  • TABLE 257. BRICS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 258. BRICS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 259. BRICS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2024 (USD MILLION)
  • TABLE 260. BRICS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2025-2032 (USD MILLION)
  • TABLE 261. BRICS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 262. BRICS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2025-2032 (USD MILLION)
  • TABLE 263. BRICS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 264. BRICS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 265. G7 PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 266. G7 PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 267. G7 PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2024 (USD MILLION)
  • TABLE 268. G7 PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2025-2032 (USD MILLION)
  • TABLE 269. G7 PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 270. G7 PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 271. G7 PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2024 (USD MILLION)
  • TABLE 272. G7 PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2025-2032 (USD MILLION)
  • TABLE 273. G7 PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 274. G7 PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2025-2032 (USD MILLION)
  • TABLE 275. G7 PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 276. G7 PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 277. NATO PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 278. NATO PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 279. NATO PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2024 (USD MILLION)
  • TABLE 280. NATO PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2025-2032 (USD MILLION)
  • TABLE 281. NATO PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 282. NATO PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 283. NATO PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2024 (USD MILLION)
  • TABLE 284. NATO PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2025-2032 (USD MILLION)
  • TABLE 285. NATO PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 286. NATO PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2025-2032 (USD MILLION)
  • TABLE 287. NATO PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 288. NATO PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 289. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 290. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 291. UNITED STATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2024 (USD MILLION)
  • TABLE 292. UNITED STATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2025-2032 (USD MILLION)
  • TABLE 293. UNITED STATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 294. UNITED STATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2025-2032